COVID-19
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
At least three different biotech companies are working on two ACE2-related drugs to find a solution to the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
China’s CanSino Biologics is advancing its COVID-19 vaccine candidate into Phase II, putting the company ahead of others in the race against the novel coronavirus.
The goal is to connect trial sites, sponsors and clinical research organizations to speed COVID-19 clinical trials for vaccines, drugs and diagnostics.
Anyone who breathes is at risk for contracting COVID-19, the disease caused by the novel coronavirus, and the estimated 36 million Americans who have lung diseases are even more at risk for developing severe complications related to the disease.
If you’re having trouble keeping up with multiple industry programs aimed at COVID-19, you’re not alone. But, there is a new solution that can help you see the proverbial forest from the trees – Signals Analytics COVID-19 Playbook.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Pfizer and BioNTech updated their development program, with plans to launch clinical trials in the U.S. and Europe across multiple sites by the end of April.
The world continues to wait with bated breath for a treatment for COVID-19, and Pluristem Therapeutics appears to be on the cusp of providing some hope.
PRESS RELEASES